Quote:

---

LLY's MAB targets viral proteins and trial for critical patients has been stopped due to no perceived / observed benefit. This will happen to every MAB targeting viral spike proteins eventually, as mutations reduce binding site affinity.

---

While I agree viral mutations are a threat to all viral targeting MABs, I think the primary reason therapeutics like these won't help severe/critical populations (as opposed to LL) is because at that stage, the disease is more about immune disfunction rather than viral infection, as the good Dr. P reported several months ago.

That said, these MABs might offer significant benefit if administered very early in the infection cycle - IF you can figure out which patients were just infected. That's the rub.